8-K: Connect Biopharma Initiates Phase 2 Study of Rademikibart for Acute Asthma Exacerbations

Connect Biopharma has commenced a Phase 2 clinical trial to assess the safety and efficacy of rademikibart in treating acute asthma exacerbations.

Summary

• Connect Biopharma has initiated a Phase 2 clinical trial, named Seabreeze STAT Asthma study, to evaluate rademikibart for acute asthma exacerbations.
• The study follows a written agreement on the final study protocol from the FDA.
• Rademikibart is being assessed as an adjunct to standard of care for adults and adolescents with asthma and type 2 inflammation.
• The company expects to report topline data from the study in the first half of 2026.
• The trial aims to enroll approximately 160 participants globally.
• The primary endpoint is the safety and efficacy of rademikibart, measured by the treatment failure rate over 28 days.
• Secondary endpoints include exacerbation rates, symptom scores, lung function (FEV1), and adverse event incidence.
• A prior Phase 2 trial showed rapid improvements in lung function within 24 hours and sustained improvements through 24 weeks, especially in patients with eosinophil counts 300 cells/L or higher.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the initiation of a Phase 2 trial and promising prior data, but tempered by the inherent risks of drug development.

Positives

• Initiation of Phase 2 trial indicates progress in clinical development of rademikibart.
• FDA agreement on study protocol suggests regulatory alignment.
• Prior Phase 2 data showed rapid improvement in lung function with rademikibart.
• The study targets a significant unmet need in acute asthma exacerbations, affecting approximately 1 million patients annually in the U.S.
• Rademikibart has the potential to be the first biologic indicated for patients experiencing an acute exacerbation of asthma.

Risks

• The forward-looking statements are subject to risks and uncertainties, including unexpected safety or efficacy data, adverse safety events, and delays.
• Drug development and commercialization involve a high degree of risk, and early-stage clinical trial results may not be indicative of later-stage results or regulatory approval.
• The company relies on third parties to conduct clinical trials and manufacture product candidates.

Future Outlook

The company expects to report topline data from the Phase 2 Seabreeze STAT Asthma study in the first half of 2026 and is on track to initiate a similarly-designed Phase 2 study in patients with COPD imminently.

Management Comments

• Barry Quart, Pharm.D., CEO and Director of Connect Biopharma, stated that rademikibart has demonstrated a differentiated clinical profile, delivering robust improvements in pulmonary function in less than 24 hours.
• Mario Castro, M.D., MPH, Professor of Medicine at University of Kansas Medical Center, is encouraged by the data generated to date with rademikibart, highlighting rapid and sustained improvements in lung function in patients, particularly those with high eosinophil count.

Industry Context

This announcement is relevant to the biopharmaceutical industry, specifically companies developing treatments for respiratory diseases like asthma and COPD. The focus on acute exacerbations addresses a significant unmet need in these patient populations.

Comparison to Industry Standards

• Rademikibart's potential to improve lung function within 24 hours is a key differentiator, as no other biologic has demonstrated this rapid effect to date.
• Competitors in the asthma and COPD space include companies like AstraZeneca, GlaxoSmithKline, and Regeneron, which offer biologics and other therapies for chronic management of these conditions.
• The study's focus on acute exacerbations positions rademikibart as a potential first-in-class treatment for this specific indication.

Stakeholder Impact

• Positive impact on asthma patients experiencing acute exacerbations if rademikibart proves effective.
• Potential benefit to healthcare providers by offering a new treatment option.
• Potential positive impact on shareholders if the trial is successful and rademikibart is approved.

Next Steps

• Enrollment of approximately 160 participants in the Seabreeze STAT Asthma study.
• Initiation of a similarly-designed Phase 2 study in patients with COPD.
• Reporting of topline data from the Seabreeze STAT Asthma study in the first half of 2026.

Key Dates

Keywords

rademikibart, asthma, COPD, clinical trial, Phase 2, acute exacerbation, Connect Biopharma, FDA, biopharmaceutical